Actively Recruiting
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2025-12-18
240
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
CONDITIONS
Official Title
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years and older
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of at least 3 months
- Signed informed consent form
You will not qualify if you...
- Known uncontrolled or symptomatic central nervous system metastases
- Previous anticancer treatment adverse events greater than grade 1 (except alopecia and fatigue) according to NCI CTCAE v5.0
- Inadequate organ or bone marrow function
- Pregnant or breastfeeding women
- Known allergies, hypersensitivity, or intolerance to SSGJ-706
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of The Shanghai Pulmonary Hospital
Shanghai, China
Actively Recruiting
Research Team
S
Shengxiang Ren
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here